Marpai (MRAI) Competitors

$0.28 0.00 (0.00%)

As of 05/22/2026 03:56 PM Eastern

MRAI vs. BMGL, ACON, ADVB, MGRX, and BRTX

Should you buy Marpai stock or one of its competitors? MarketBeat compares Marpai with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marpai include Basel Medical Group (BMGL), Aclarion (ACON), Advanced Biomed (ADVB), Mangoceuticals (MGRX), and Biorestorative Therapies (BRTX). These companies are all part of the "healthcare" industry.

How does Marpai compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Basel Medical Group has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Marpai has a beta of 4.38, indicating that its stock price is 338% more volatile than the broader market.

Basel Medical Group has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

In the previous week, Basel Medical Group had 1 more articles in the media than Marpai. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for Marpai. Basel Medical Group's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Basel Medical Group	Neutral
Marpai	Neutral

Basel Medical Group has higher earnings, but lower revenue than Marpai.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.26	-$9.50M	N/A	N/A
Marpai	$34.87M	0.20	-$28.75M	-$0.87	N/A

Summary

Basel Medical Group beats Marpai on 6 of the 10 factors compared between the two stocks.

How does Marpai compare to Aclarion?

Aclarion (NASDAQ:ACON) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Marpai has a net margin of -85.70% compared to Aclarion's net margin of -10,320.51%. Marpai's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Marpai	-85.70%	N/A	-100.23%

Aclarion has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Marpai has a beta of 4.38, indicating that its share price is 338% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.5% of Aclarion shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 0.8% of Aclarion shares are held by insiders. Comparatively, 46.1% of Marpai shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aclarion has higher earnings, but lower revenue than Marpai. Aclarion is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	98.71	-$7.23M	-$9.03	N/A
Marpai	$34.87M	0.20	-$28.75M	-$0.87	N/A

In the previous week, Aclarion's average media sentiment score of 1.00 beat Marpai's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.

Company	Overall Sentiment
Aclarion	Positive
Marpai	Neutral

Summary

Marpai beats Aclarion on 8 of the 13 factors compared between the two stocks.

How does Marpai compare to Advanced Biomed?

Marpai (NASDAQ:MRAI) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Advanced Biomed has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Advanced Biomed's return on equity of 87.74% beat Marpai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Advanced Biomed	N/A	87.74%	64.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Advanced Biomed has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.20	-$28.75M	-$0.87	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	0.82

In the previous week, Marpai's average media sentiment score of 0.00 equaled Advanced Biomed'saverage media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
Advanced Biomed	Neutral

49.8% of Marpai shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 34.4% of Advanced Biomed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Marpai has a beta of 4.38, indicating that its stock price is 338% more volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Advanced Biomed beats Marpai on 7 of the 11 factors compared between the two stocks.

How does Marpai compare to Mangoceuticals?

Marpai (NASDAQ:MRAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Marpai has a beta of 4.38, suggesting that its share price is 338% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

49.8% of Marpai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Mangoceuticals had 1 more articles in the media than Marpai. MarketBeat recorded 1 mentions for Mangoceuticals and 0 mentions for Marpai. Marpai's average media sentiment score of 0.00 beat Mangoceuticals' score of -0.32 indicating that Marpai is being referred to more favorably in the media.

Company	Overall Sentiment
Marpai	Neutral
Mangoceuticals	Neutral

Mangoceuticals has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.20	-$28.75M	-$0.87	N/A
Mangoceuticals	$460K	16.83	-$20.64M	-$1.49	N/A

Summary

Marpai beats Mangoceuticals on 9 of the 14 factors compared between the two stocks.

How does Marpai compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

In the previous week, Biorestorative Therapies' average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Marpai	Neutral

Marpai has a net margin of -85.70% compared to Biorestorative Therapies' net margin of -3,088.27%. Marpai's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Marpai	-85.70%	N/A	-100.23%

Biorestorative Therapies has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Marpai has a beta of 4.38, meaning that its share price is 338% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by insiders. Comparatively, 46.1% of Marpai shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biorestorative Therapies has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	14.72	-$14.24M	-$1.07	N/A
Marpai	$34.87M	0.20	-$28.75M	-$0.87	N/A

Summary

Marpai beats Biorestorative Therapies on 8 of the 12 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	health & allied services, not elsewhere classified Industry	Business Sector	NASDAQ Exchange
Market Cap	$7.09M	$79.35M	$6.52B	$12.34B
Dividend Yield	N/A	N/A	3.02%	5.28%
P/E Ratio	-0.11	0.74	30.49	25.65
Price / Sales	0.20	0.15	422.61	86.28
Price / Cash	N/A	4.19	24.55	56.67
Price / Book	-0.16	0.15	6.78	7.14
Net Income	-$28.75M	$25.15M	$204.61M	$335.98M
7 Day Performance	1.82%	0.61%	2.11%	4.15%
1 Month Performance	1.97%	0.66%	-0.71%	2.54%
1 Year Performance	-79.86%	-29.95%	33.61%	35.05%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$0.28 flat	N/A	-79.9%	$7.09M	$34.87M	N/A	150	Gap Down High Trading Volume
BMGL Basel Medical Group	0.141 of 5 stars	$0.75 -2.4%	N/A	-56.4%	$14.34M	$8.90M	N/A	36	Positive News
ACON Aclarion	1.1783 of 5 stars	$3.28 +4.1%	N/A	-52.1%	$7.76M	$80K	N/A	7	Analyst Upgrade
ADVB Advanced Biomed	1.0817 of 5 stars	$4.75 -9.2%	N/A	N/A	$7.14M	N/A	1.25	40
MGRX Mangoceuticals	1.018 of 5 stars	$0.34 -1.6%	N/A	-73.3%	$5.86M	$460K	N/A	3	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. BMGL, ACON, ADVB, MGRX, and BRTX

How does Marpai compare to Basel Medical Group?

Summary

How does Marpai compare to Aclarion?

Summary

How does Marpai compare to Advanced Biomed?

Summary

How does Marpai compare to Mangoceuticals?

Summary

How does Marpai compare to Biorestorative Therapies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. BMGL, ACON, ADVB, MGRX, and BRTX

How does Marpai compare to Basel Medical Group?

Do analysts prefer BMGL or MRAI?

Do institutionals and insiders hold more shares of BMGL or MRAI?

Which has more volatility and risk, BMGL or MRAI?

Is BMGL or MRAI more profitable?

Does the media favor BMGL or MRAI?

Which has higher earnings and valuation, BMGL or MRAI?

Summary

How does Marpai compare to Aclarion?

Is ACON or MRAI more profitable?

Which has more volatility and risk, ACON or MRAI?

Do analysts recommend ACON or MRAI?

Do institutionals & insiders believe in ACON or MRAI?

Which has higher valuation & earnings, ACON or MRAI?

Does the media refer more to ACON or MRAI?

Summary

How does Marpai compare to Advanced Biomed?

Is MRAI or ADVB more profitable?

Do analysts recommend MRAI or ADVB?

Which has stronger earnings and valuation, MRAI or ADVB?

Does the media prefer MRAI or ADVB?

Do institutionals & insiders believe in MRAI or ADVB?

Which has more volatility & risk, MRAI or ADVB?

Summary

How does Marpai compare to Mangoceuticals?

Is MRAI or MGRX more profitable?

Do analysts prefer MRAI or MGRX?

Which has more risk & volatility, MRAI or MGRX?

Do institutionals and insiders believe in MRAI or MGRX?

Does the media prefer MRAI or MGRX?

Which has preferable earnings and valuation, MRAI or MGRX?

Summary

How does Marpai compare to Biorestorative Therapies?

Does the media favor BRTX or MRAI?

Is BRTX or MRAI more profitable?

Which has more risk and volatility, BRTX or MRAI?

Do analysts rate BRTX or MRAI?

Do insiders & institutionals believe in BRTX or MRAI?

Which has preferable earnings and valuation, BRTX or MRAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools